Solid Biosciences Beheer

Beheer criteriumcontroles 3/4

De CEO Solid Biosciences is Bo Cumbo, benoemd in Dec2022, heeft een ambtstermijn van 1.92 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 918.55K, bestaande uit 63.7% salaris en 36.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.045% van de aandelen van het bedrijf, ter waarde $ 100.26K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.9 jaar en 7.9 jaar.

Belangrijke informatie

Bo Cumbo

Algemeen directeur

US$918.6k

Totale compensatie

Percentage CEO-salaris	63.7%
Dienstverband CEO	1.9yrs
Eigendom CEO	0.05%
Management gemiddelde ambtstermijn	1.9yrs
Gemiddelde ambtstermijn bestuur	7.9yrs

Recente managementupdates

Recent updates

Analysts Have Lowered Expectations For Solid Biosciences Inc. (NASDAQ:SLDB) After Its Latest Results

Apr 30

Some Analysts Just Cut Their Solid Biosciences Inc. (NASDAQ:SLDB) Estimates

Apr 28

We're Keeping An Eye On Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

Mar 17

Solid Biosciences (NASDAQ:SLDB) Is In A Good Position To Deliver On Growth Plans

Oct 28

We're Not Very Worried About Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

Jul 13

We're Hopeful That Solid Biosciences (NASDAQ:SLDB) Will Use Its Cash Wisely

Mar 17

Soild Bio sinks 13% after Sarepta data misses goal

Jan 08

Solid Biosciences launches $90M private placement

Dec 11

Solid Biosciences: Does Not Look Like A Solid Investment Given Its Unsatisfactory Trial Data

Nov 10

Analyse CEO-vergoeding

Hoe is Bo Cumbo's beloning veranderd ten opzichte van Solid Biosciences's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$91m
Mar 31 2024	n/a	n/a	-US$90m
Dec 31 2023	US$919k	US$585k	-US$96m
Sep 30 2023	n/a	n/a	-US$91m
Jun 30 2023	n/a	n/a	-US$90m
Mar 31 2023	n/a	n/a	-US$91m
Dec 31 2022	US$4m	US$46k	-US$86m

Compensatie versus markt: De totale vergoeding ($USD 918.55K ) Bo } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 1.48M ).

Compensatie versus inkomsten: De vergoeding van Bo is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Bo Cumbo (53 yo)

1.9yrs

Tenure

US$918,550

Compensatie

Mr. Alexander G. Cumbo, also known as Bo, serves as President, Chief Executive Officer and Director at Solid Biosciences Inc. since December 02, 2022. He serves as Independent Director of Verve Therapeutic...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Ian Smith	Executive Chair	4.6yrs	US$828.65k	0.28% $ 630.9k
Alexander Cumbo	President	1.9yrs	US$918.55k	0.045% $ 100.3k
Ilan Ganot	Co-founder	11.8yrs	US$902.09k	0.32% $ 711.3k
Kevin Tan	CFO & Treasurer	1.8yrs	US$1.36m	0.024% $ 53.5k
David Howton	COO, General Counsel & Secretary	1.9yrs	US$648.88k	0.020% $ 44.2k
Annie Ganot	Co-Founder & Head of Patient Advocacy	no data	geen gegevens	geen gegevens
Paul Herzich	Chief Technology Officer	1.9yrs	geen gegevens	0.016% $ 34.6k
Allison Bogosian	Senior Vice President of Human Resources	2.8yrs	geen gegevens	geen gegevens
Jessie Hanrahan	Chief Regulatory Officer	1.9yrs	geen gegevens	0.018% $ 40.1k
Shuli Kulak	Head of Corporate Strategy & Business Development	1.2yrs	geen gegevens	geen gegevens
Gabriel Brooks	Chief Medical Officer	1.1yrs	geen gegevens	0.028% $ 63.1k

1.9yrs

Gemiddelde duur

49yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van SLDB wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.9 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Ian Smith	Executive Chair	4.6yrs	US$828.65k	0.28% $ 630.9k
Alexander Cumbo	President	1.9yrs	US$918.55k	0.045% $ 100.3k
Ilan Ganot	Co-founder	11.8yrs	US$902.09k	0.32% $ 711.3k
Jeffrey Bluestone	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Geoffrey Slaff	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Laurence Turka	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Jeffrey Chamberlain	Chairman of Scientific Advisory Board	6.8yrs	geen gegevens	geen gegevens
Adam Stone	Lead Independent Director	9yrs	US$109.72k	0% $ 0
Lynne Sullivan	Independent Director	9yrs	US$113.22k	0% $ 0
Carrie Miceli	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Ronald Cohn	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Dongsheng Duan	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens

7.9yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van SLDB wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.9 jaar).

Solid Biosciences Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Solid Biosciences Inc. Announces Board Resignations

Solid Biosciences Inc., Annual General Meeting, Jun 11, 2024

Solid Biosciences Inc. Appoints Gabriel Brooks as Chief Medical Officer

Solid Biosciences Inc. Announces Executive Changes

Solid Biosciences Appoints Kevin Tan as Chief Financial Officer

Solid Biosciences Inc. Announces Executive Changes

Recent updates

Price target decreased by 9.0% to US$18.00

We Think Solid Biosciences (NASDAQ:SLDB) Can Afford To Drive Business Growth

Price target increased by 13% to US$19.78

Consensus revenue estimates increase by 123%

Solid Biosciences Inc. Announces Board Resignations

Solid Biosciences Inc., Annual General Meeting, Jun 11, 2024

Buy Solid Biosciences: Unpacking Its Main Value Driver

Solid Biosciences Inc. Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

Consensus EPS estimates upgraded to US$2.79 loss

Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid

Solid Biosciences Inc. announced that it expects to receive $108.858551 million in funding from a group of investors

Solid Biosciences Announces IND Clearance by FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate Sgt-003

Consensus revenue estimates decrease by 50%, EPS upgraded

New minor risk - Share price stability

Solid Biosciences Inc. Appoints Gabriel Brooks as Chief Medical Officer

Consensus revenue estimates decrease by 33%, EPS upgraded

New major risk - Revenue size

New minor risk - Market cap size

Solid Biosciences Inc. Announces Executive Changes

First quarter 2023 earnings released: US$1.54 loss per share (vs US$3.37 loss in 1Q 2022)

Full year 2022 earnings: EPS misses analyst expectations

Solid Biosciences Inc. and Phlox Therapeutics Announce Strategic Research Collaboration Focused on Accelerating the Development of New Therapies for Rare Cardiac Diseases

Solid Biosciences Appoints Kevin Tan as Chief Financial Officer

Solid Biosciences Inc. Announces Executive Changes

Consensus forecasts updated

Consensus forecasts updated

Third quarter 2022 earnings released: US$2.71 loss per share (vs US$2.40 loss in 3Q 2021)

Third quarter 2022 earnings released: US$2.71 loss per share (vs US$2.40 loss in 3Q 2021)

Consensus forecasts updated

Price target decreased to US$3.00

Solid Biosciences Inc. Reports Additional Preclinical Data Demonstrating that its Novel Capsid, AAV-SLB101, Provides Superior Transduction Efficiency and Enhanced Distribution to Skeletal Muscle

Solid Biosciences Presents New SGT-001 IGNITE DMD Study Results

Consensus forecasts updated

Solid Biosciences Inc. (NasdaqGS:SLDB) entered into a definitive agreement to acquire AavantiBio, Inc.

Solid Biosciences to acquire gene therapy company AavantiBio

Bain Capital Engages in Discussions with Solid Biosciences

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Solid Biosciences Receives Deficiency Letter from the Listing Qualifications Department of the Nasdaq for Minimum Bid Price Requirement

Price target decreased to US$5.60

Analysts Have Lowered Expectations For Solid Biosciences Inc. (NASDAQ:SLDB) After Its Latest Results

Consensus revenue estimates fall by 12%

Some Analysts Just Cut Their Solid Biosciences Inc. (NASDAQ:SLDB) Estimates

Price target decreased to US$8.67

Solid Biosciences Inc. to Report Q1, 2022 Results on Apr 27, 2022

Price target decreased to US$8.67

We're Keeping An Eye On Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

Price target decreased to US$7.40

Price target decreased to US$7.42

Price target decreased to US$8.50

Solid Biosciences (NASDAQ:SLDB) Is In A Good Position To Deliver On Growth Plans

Solid Biosciences Inc. Reports 1.5-Year Data from Patients in the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001

Solid Biosciences Inc. to Provide Update on Long-Term Outcomes Data from Patients in the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001

Consensus forecasts updated

We're Not Very Worried About Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

Solid Biosciences Inc.(NasdaqGS:SLDB) dropped from Russell 2500 Growth Index

Co-Founder & Independent Director Matthew Arnold has left the company

Solid Biosciences Inc Announces Two Additional Patients Dosed in the IGNITE DMD Clinical Trial

We're Hopeful That Solid Biosciences (NASDAQ:SLDB) Will Use Its Cash Wisely

Solid Biosciences Reports Efficacy and Safety Data from the Ongoing Ignite Dmd Clinical Trial and Resumption of Patient Dosing in the 2E14 Vg/Kg Cohort

Solid Biosciences Inc. Announces Management Changes

New 90-day high: US$9.74

CFO & Treasurer has left the company

Co-founder exercised options and sold US$66k worth of stock

Soild Bio sinks 13% after Sarepta data misses goal

New 90-day high: US$7.79

New 90-day high: US$5.60

Solid Biosciences launches $90M private placement

Solid Biosciences Inc. Announces Management Changes